Total number of products available locally rises to 10
Eye disease treatment also set for launch by year-end

Celltrion has launched an autoimmune disease treatment and a bone disease treatment in Brazil, Latin America's largest pharmaceutical market. The launches bring the total number of Celltrion products available in Brazil to 10.

Product image of Celltrion's bone disease treatment Stoboclo. Celltrion

Product image of Celltrion's bone disease treatment Stoboclo. Celltrion

View original image

On November 5, Celltrion said its Brazilian subsidiary launched the autoimmune disease treatment Coyvolma (active ingredient: ustekinumab) and the bone disease treatments Stoboclo and Osenvelt (active ingredient: denosumab) in Brazil last month.


Coyvolma is sold under the name Steqeyma in major markets, including the United States, and is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Coyvolma was launched in prefilled syringes (45 mg and 90 mg) and vials (130 mg), while Stoboclo was launched in prefilled syringes (60 mg) and Osenvelt in vials (120 mg).


Celltrion plans to use its established sales network to quickly establish its new products in the local market. Most hospitals and clinics targeted by the new products have already used Celltrion products. In Brazil's private market, the autoimmune disease treatment Remsima has a market share of about 50%, the breast and stomach cancer treatment Herzuma about 40%, and the blood cancer treatment Truxima about 30%.


With Coyvolma added to its portfolio, Celltrion now offers treatments for infliximab, adalimumab, omalizumab, and ustekinumab in Brazil's autoimmune disease market. The company also plans to launch Eydenzelt (active ingredient: aflibercept), an eye disease treatment, and Aptozma (active ingredient: tocilizumab), an autoimmune disease treatment, by the end of the year. The launch of Eydenzelt will expand Celltrion's business in Brazil into the eye disease sector.



A Celltrion official said, "Building on the customer network and trust we have established through our existing products in Brazil, we will work to quickly establish Coyvolma, Stoboclo, and Osenvelt and expand prescriptions. We will also continue launching follow-on products without disruption to further accelerate our growth in the Latin American market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing